fbpx
CAS Insight

molecules of the month

Takeda EGFRex20 Inhibitor

EGFR exon 20 mutant inhibitor, oral once-daily

Breakthrough Therapy for ex20+ NSCLC (Ph. I)

from cellular screening + SBDD

mobocertinib

ARIAD/Takeda, Cambridge, MA

mobocertinib takeda TAK structure EGFR exon 20 inhibitor ex20 Drug Hunter molecules of the year
1 min read

The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 20 insertion mutations.  The appearance of exon 20 insertions is a common resistance mechanism to earlier generations of EGFR inhibitors including osimertinib, to which TAK-788 is structurally related. 1st and 2nd generation EGFR inhibitors partly depend on the fact that mutant forms of EGFR have destabilized inactive forms with reduced ATP affinity relative to wild-type (WT) EGFR, making the mutant forms easier to drug in cells. EGFR exon 20 mutants, however, have active sites that are very similar to WT, making tumors bearing these mutations difficult to drug without significant side effects due to WT inhibition. This oral…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: